BR112012019866A2 - composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto - Google Patents
composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um compostoInfo
- Publication number
- BR112012019866A2 BR112012019866A2 BR112012019866A BR112012019866A BR112012019866A2 BR 112012019866 A2 BR112012019866 A2 BR 112012019866A2 BR 112012019866 A BR112012019866 A BR 112012019866A BR 112012019866 A BR112012019866 A BR 112012019866A BR 112012019866 A2 BR112012019866 A2 BR 112012019866A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- pharmaceutical composition
- viral infections
- treating viral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto. são fornecidos, inter alia, composto da fómula (i) úteis como inibidores de ciclofilina.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1002097.2A GB201002097D0 (en) | 2010-02-09 | 2010-02-09 | Novel compounds |
GBGB1006128.1A GB201006128D0 (en) | 2010-04-13 | 2010-04-13 | Novel compounds |
GBGB1101085.7A GB201101085D0 (en) | 2011-01-21 | 2011-01-21 | Novel compounds |
PCT/GB2011/050236 WO2011098809A1 (en) | 2010-02-09 | 2011-02-09 | Sanglifehrin based compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012019866A2 true BR112012019866A2 (pt) | 2017-07-11 |
BR112012019866A8 BR112012019866A8 (pt) | 2017-12-26 |
Family
ID=43836693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012019866A BR112012019866A8 (pt) | 2010-02-09 | 2011-02-09 | Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto |
Country Status (9)
Country | Link |
---|---|
US (1) | US9119853B2 (pt) |
EP (1) | EP2533784B1 (pt) |
JP (1) | JP5894935B2 (pt) |
AU (1) | AU2011214135B2 (pt) |
BR (1) | BR112012019866A8 (pt) |
CA (1) | CA2788761C (pt) |
ES (1) | ES2541853T3 (pt) |
MX (1) | MX2012008873A (pt) |
WO (1) | WO2011098809A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201008123D0 (en) * | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
GB201118334D0 (en) * | 2011-10-24 | 2011-12-07 | Biotica Tech Ltd | Novel dosage form |
US10857150B2 (en) | 2016-11-18 | 2020-12-08 | Abliva Ab | Use of sanglifehrin macrocyclic analogues as anticancer compounds |
CA3123869A1 (en) * | 2018-12-21 | 2020-06-25 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
CR20220241A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
EP0910633B1 (en) | 1996-07-05 | 2009-12-09 | Biotica Technology Limited | Hybrid polyketide synthase I gene |
GB9814622D0 (en) | 1998-07-06 | 1998-09-02 | Biotica Tech Ltd | Polyketides,their preparation,and materials for use therein |
CN101242842A (zh) | 2005-06-17 | 2008-08-13 | 诺瓦提斯公司 | Sanglifehrin在hcv中的用途 |
WO2008084368A2 (en) | 2007-01-04 | 2008-07-17 | Debiopharm Sa | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
EP2342335B1 (en) | 2008-09-24 | 2015-09-16 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Novel gene cluster |
JO3063B1 (ar) | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
-
2011
- 2011-02-09 AU AU2011214135A patent/AU2011214135B2/en not_active Ceased
- 2011-02-09 BR BR112012019866A patent/BR112012019866A8/pt not_active Application Discontinuation
- 2011-02-09 MX MX2012008873A patent/MX2012008873A/es active IP Right Grant
- 2011-02-09 US US13/575,212 patent/US9119853B2/en active Active
- 2011-02-09 CA CA2788761A patent/CA2788761C/en not_active Expired - Fee Related
- 2011-02-09 WO PCT/GB2011/050236 patent/WO2011098809A1/en active Application Filing
- 2011-02-09 EP EP20110704308 patent/EP2533784B1/en not_active Not-in-force
- 2011-02-09 JP JP2012552469A patent/JP5894935B2/ja not_active Expired - Fee Related
- 2011-02-09 ES ES11704308.3T patent/ES2541853T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
AU2011214135A1 (en) | 2012-08-23 |
BR112012019866A8 (pt) | 2017-12-26 |
JP5894935B2 (ja) | 2016-03-30 |
US20120295841A1 (en) | 2012-11-22 |
AU2011214135B2 (en) | 2014-07-31 |
WO2011098809A1 (en) | 2011-08-18 |
CA2788761C (en) | 2018-05-29 |
JP2013518923A (ja) | 2013-05-23 |
CN102770139A (zh) | 2012-11-07 |
CA2788761A1 (en) | 2011-08-18 |
US9119853B2 (en) | 2015-09-01 |
EP2533784B1 (en) | 2015-04-22 |
EP2533784A1 (en) | 2012-12-19 |
ES2541853T3 (es) | 2015-07-27 |
MX2012008873A (es) | 2012-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018009252A2 (pt) | tratamento da osteoartrite | |
CR20140361A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
CR20120296A (es) | Nuevos compuestos de espiropiperidina | |
UA111161C2 (uk) | Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування | |
CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
EA201590879A1 (ru) | Арилконденсированные и гетероарилконденсированные лактамы | |
MX2011005934A (es) | Compuestos organicos. | |
EA201301209A1 (ru) | Производные пирролотриазинона в качестве ингибиторов p13k | |
CL2012002057A1 (es) | Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales. | |
BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
BR112012027062B8 (pt) | composto, processo para a preparação de um composto e usos do mesmo | |
BR112013004662B8 (pt) | Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica | |
ECSP11011184A (es) | Compuestos orgánicos | |
CO6362015A2 (es) | Derivados de acido 1-amino-2ciclobutiletilboronico | |
CL2015001667A1 (es) | Derivados de manosa para tratar infecciones bacterianas. | |
MY165087A (en) | Neprilysin inhibitors | |
EA201490724A1 (ru) | Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia | |
EA201791850A1 (ru) | Борсодержащие малые молекулы | |
IN2014KN00948A (pt) | ||
CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
ECSP14013239A (es) | Composiciones farmacéuticas | |
BR112013024965A2 (pt) | composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto | |
BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
BR112013016241A2 (pt) | composto, e, método para fabricar um composto | |
BR112015006037A2 (pt) | métodos para tratamento de hcv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: BIOTICA TECHNOLOGY LIMITED (GB) |
|
B25A | Requested transfer of rights approved |
Owner name: NEUROVIVE PHARMACEUTICAL AB (SE) |
|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |